{"id":32124,"date":"2014-09-25T10:55:57","date_gmt":"2014-09-25T14:55:57","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=32124"},"modified":"2014-09-25T10:56:44","modified_gmt":"2014-09-25T14:56:44","slug":"merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124","title":{"rendered":"Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/25\/2014 (wallstreetpr) \u2013\u00a0<strong>Merrimack Pharmaceuticals Inc (NASDAQ:MACK)<\/strong> seeks to work with <strong>Baxter International Inc. (NYSE:BAX)<\/strong> in the development and marketing of its pancreatic cancer drug outside the U.S.<\/p>\n<p style=\"text-align: justify;\"><strong>Terms Of Agreement<\/strong><\/p>\n<p style=\"text-align: justify;\">According to a Reuters\u2019 <a href=\"http:\/\/finance.yahoo.com\/news\/baxter-market-merrimacks-cancer-drug-120824683.html\" target=\"_blank\">report<\/a>, Merrimack and Baxter will work in partnership to expand the market of Merrimack\u2019s pancreatic drug outside of the country. According to the deal, Merrimack would be entitled to get as much as $100 million as an upfront payment from Baxter International Inc. (NYSE:BAX). The payment will be completed as early as within this quarter, the companies announced. Apart from this, Baxter will give another $120 million to Merrimack Pharmaceuticals Inc (NASDAQ:MACK) as milestone payments for its drug, called MM-398.<\/p>\n<p style=\"text-align: justify;\"><strong>Advancing Development<\/strong><\/p>\n<p style=\"text-align: justify;\">The licensing agreement would fetch Merrimack additional $280 million in lieu of development of the drug. The cost also encompasses milestone payments that Baxter International Inc. (NYSE:BAX) would be liable to pay to Merrimack in case the drug shows successful results in treating another form of pancreatic cancer. Apart from this, Baxter will be due to pay another $220 million to the drug developing company if the drug is rendered approval to treat two other indications. Merrimack Pharmaceuticals Inc (NASDAQ:MACK)\u00a0is already carrying out the development of the drug for two new indications, it said. However, the drug developer is eligible to retain all rights of marketing the drug in the U.S., according to the terms of the contract. In addition, marketing rights in Taiwan are separate, the companies informed.<\/p>\n<p style=\"text-align: justify;\"><strong>Expanding Market<\/strong><\/p>\n<p style=\"text-align: justify;\">Merrimack Pharmaceuticals Inc (NASDAQ:MACK) is currently seeking approval from the U.S. Food and Drug Administration to market the drug, MM-398 that aims at treating pancreatic cancer, in other parts of the world. The company is in the process of filing an approval application with the FDA for selling it outside of the U.S. Merrimack wants to start marketing its drug in other countries by the beginning of 2015.<\/p>\n<p style=\"text-align: justify;\">Shares of the company surged quickly with the announcement. Upon closing of the trade yesterday, figures reached $8.95, marking a surge of as much as 24%.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/25\/2014 (wallstreetpr) \u2013\u00a0Merrimack Pharmaceuticals Inc (NASDAQ:MACK) seeks to work with Baxter International Inc. (NYSE:BAX) in the development and marketing of its pancreatic cancer [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":32125,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3853,6260,6261,3854],"stock_ticker":[],"class_list":["post-32124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-baxter-international-inc-nysebax","tag-merrimack-pharmaceuticals-inc-nasdaqmack","tag-nasdaqmack","tag-nysebax","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/25\/2014 (wallstreetpr) \u2013\u00a0Merrimack Pharmaceuticals Inc (NASDAQ:MACK) seeks to work with Baxter International Inc. (NYSE:BAX) in the development and marketing of its pancreatic cancer [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-25T14:55:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-09-25T14:56:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Merrimack-Pharmaceuticals-Inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"299\" \/>\n\t<meta property=\"og:image:height\" content=\"169\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug\",\"datePublished\":\"2014-09-25T14:55:57+00:00\",\"dateModified\":\"2014-09-25T14:56:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124\"},\"wordCount\":365,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Merrimack-Pharmaceuticals-Inc.jpg\",\"keywords\":[\"Baxter International Inc. (NYSE:BAX)\",\"Merrimack Pharmaceuticals Inc (NASDAQ:MACK)\",\"NASDAQ:MACK\",\"NYSE:BAX\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124\",\"name\":\"Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Merrimack-Pharmaceuticals-Inc.jpg\",\"datePublished\":\"2014-09-25T14:55:57+00:00\",\"dateModified\":\"2014-09-25T14:56:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Merrimack-Pharmaceuticals-Inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Merrimack-Pharmaceuticals-Inc.jpg\",\"width\":299,\"height\":169},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124","og_locale":"en_US","og_type":"article","og_title":"Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug  - Wall Street PR","og_description":"Boston, MA 09\/25\/2014 (wallstreetpr) \u2013\u00a0Merrimack Pharmaceuticals Inc (NASDAQ:MACK) seeks to work with Baxter International Inc. (NYSE:BAX) in the development and marketing of its pancreatic cancer [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-25T14:55:57+00:00","article_modified_time":"2014-09-25T14:56:44+00:00","og_image":[{"width":299,"height":169,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Merrimack-Pharmaceuticals-Inc.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug","datePublished":"2014-09-25T14:55:57+00:00","dateModified":"2014-09-25T14:56:44+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124"},"wordCount":365,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Merrimack-Pharmaceuticals-Inc.jpg","keywords":["Baxter International Inc. (NYSE:BAX)","Merrimack Pharmaceuticals Inc (NASDAQ:MACK)","NASDAQ:MACK","NYSE:BAX"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124","url":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124","name":"Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Merrimack-Pharmaceuticals-Inc.jpg","datePublished":"2014-09-25T14:55:57+00:00","dateModified":"2014-09-25T14:56:44+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Merrimack-Pharmaceuticals-Inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/Merrimack-Pharmaceuticals-Inc.jpg","width":299,"height":169},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merrimack-pharmaceuticals-inc-nasdaqmack-ties-up-with-baxter-international-inc-nysebax-to-sell-pancreatic-cancer-drug-32124#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ties-Up With Baxter International Inc. (NYSE:BAX) To Sell Pancreatic Cancer Drug"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=32124"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32124\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/32125"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=32124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=32124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=32124"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=32124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}